HALOZYME THERAPEUTICS INC
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
In February 2024, our Board of Directors authorized a new capital return program to repurchase up to $750.0 million of our outstanding common stock.
The table below sets forth information regarding repurchases during the three months ended March 31, 2025:
| Period · Total Number of Shares Purchased · Weighted-Average Price paid per share · Total Number of Shares Purchased as Part of Publicly Announced Programs · Approximate Dollar Value of Shares That May Yet Be purchased under the Programs (in thousands) | |||||
|---|---|---|---|---|---|
| January 1, 2025 through January 31, 2025 | — | $— | — | $500,000 | |
| February 1, 2025 through February 28, 2025 | — | $— | — | $500,000 | |
| March 1, 2025 through March 31, 2025(1) | 452,453 | $53.95 | 452,453 | $500,000 | |
| Total | 452,453 | 452,453 | |||
(1)Purchased under the share repurchase program authorized in February 2024. The shares were purchased through an ASR agreement to repurchase $250.0 million of our outstanding common stock. In December 2024, we took initial delivery of 4.2 million shares, representing approximately 80 percent of the total shares to be repurchased under the ASR agreement measured based on the closing price of our common stock on the transaction trade date. In March 2025, we finalized the transaction at an average price of $53.95 and received and an additional 0.5 million shares.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.